Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | S100B | P04271 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13913433 | 0.86 | ALDH1A1 (0.39) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL13754812 | 0.83 | S100B (0.52) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL242948 | 0.83 | S100B (0.52) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL242949 | 0.83 | S100B (0.52) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL13913452 | 0.81 | ALDH1A1 (0.52) | KMT2AALDH1A1MAPTMEN1GAA | |
| SCHEMBL5676571 | 0.80 | S100B (0.50) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL4865610 | 0.80 | S100B (0.50) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL13913448 | 0.78 | ALDH1A1 (0.50) | KMT2AALDH1A1MAPTMEN1GAA | |
| SCHEMBL13913439 | 0.77 | MAOB (0.43) | KMT2AALDH1A1MAPTMEN1GAA | |
| SCHEMBL14459250 | 0.75 | S100B (0.41) | KMT2AALDH1A1KDM4EGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382218-B2 | N-heteroaryl substituted aniline derivatives as HCV-antivirals | HOFFMANN-LA ROCHE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HOFFMANN-LA ROCHE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-20150139901-A1 | Radioactive Rhodium Complexes, Preparation Methods and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE (INSERM) (FR) | 2015-05-21 | — | — | US | disclosed |
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150139901-A1 | Radioactive Rhodium Complexes, Preparation Methods and Uses Thereof | RAB35, MRPL21, MRPS35 | KMT2A 3711/4885ALDH1A1 4118/4885MAPT 1762/4885 |
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | PLA2G4A, PLA2G1B, PLA2G4B | KMT2A 3516/4885ALDH1A1 2261/4885MAPT 3977/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | KMT2A 2951/4885ALDH1A1 1781/4885MAPT 199/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | KMT2A 1134/4885ALDH1A1 2031/4885MAPT 4518/4885 |
| US-20160000763-A1 | N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS | HAVCR2, UGT1A1, UGT1A3 | KMT2A 3664/4885ALDH1A1 105/4885MAPT 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.